VANCOUVER, British Columbia, January 2020
Lungpacer Medical, Inc., announced the completion of enrollment and follow up in its RESCUE 2 European CE Mark randomized clinical trial. This is a randomized study that enrolled a total of 110 subjects in France and Germany and evaluated the safety and effectiveness of the Lungpacer Therapy System in subjects who were expected to have ventilator-induced diaphragm dysfunction (VIDD) and be difficult to wean from mechanical ventilation. Results from the study are expected to be presented at a major conference at the end of 2020.